Abstract：
To investigate clinical features and outcomes of Chinese patients with Takotsubo syndrome (TTS).
We established the first Chinese Registry of Takotsubo Syndrome (ChiTTS Registry) and analyzed demographic, clinical, therapeutical, and outcome data to characterize clinical and outcome features of Chinese TTS patients.
In 112 enrolled patients in the ChiTTS registry from 02/01/2016 to 12/28/2021, the mean age was 59.4 ± 18.7 years old, and 27.7% were men. A total of 41.1% patients experienced respiratory and circulatory complications during hospitalization, and 17.3% patients developed cardiogenic shock. Physical triggers, dyspnea, tachycardia, and younger age (< 70 years old) predicted in-hospital complications. The MACCE rate during follow up was 13.9% per patient per year and the rate of all-cause death was 12.8% per patient per year. TTS patients with in-hospital complications developed more long-term MACCE (24.6% vs. 6.6% per patient-year, P < 0.001) and higher all-cause mortality (21.9% vs. 6.6% per patient-year, P = 0.001) than those without. The Kaplan-Meier survival analysis showed that more MACCE occurred in TTS patients with tachycardia during 3-year follow-up (HR 4.18; 95% CI 1.80-9.74; log-rank test P < 0.001). Among all medications at discharge, only beta-blocker was associated with reduced long-term MACCE (HR: 0.35; 95% CI: 0.12-0.996; P = 0.049).
We investigated clinical and outcome features of patients in the first Chinese TTS Registry. Tachycardiac TTS patients developed more inpatient and long-term adverse cardiovascular events.
We established the first Chinese Registry of Takotsubo Syndrome (ChiTTS Registry) and analyzed demographic, clinical, therapeutical, and outcome data to characterize clinical and outcome features of Chinese TTS patients.
In 112 enrolled patients in the ChiTTS registry from 02/01/2016 to 12/28/2021, the mean age was 59.4 ± 18.7 years old, and 27.7% were men. A total of 41.1% patients experienced respiratory and circulatory complications during hospitalization, and 17.3% patients developed cardiogenic shock. Physical triggers, dyspnea, tachycardia, and younger age (< 70 years old) predicted in-hospital complications. The MACCE rate during follow up was 13.9% per patient per year and the rate of all-cause death was 12.8% per patient per year. TTS patients with in-hospital complications developed more long-term MACCE (24.6% vs. 6.6% per patient-year, P < 0.001) and higher all-cause mortality (21.9% vs. 6.6% per patient-year, P = 0.001) than those without. The Kaplan-Meier survival analysis showed that more MACCE occurred in TTS patients with tachycardia during 3-year follow-up (HR 4.18; 95% CI 1.80-9.74; log-rank test P < 0.001). Among all medications at discharge, only beta-blocker was associated with reduced long-term MACCE (HR: 0.35; 95% CI: 0.12-0.996; P = 0.049).
We investigated clinical and outcome features of patients in the first Chinese TTS Registry. Tachycardiac TTS patients developed more inpatient and long-term adverse cardiovascular events.
摘要：
目的：探讨中国Takotsubo综合征(TTS)患者的临床特点及转归。
方法：我们建立了中国第一个Takotsubo综合征注册中心（ChiTTS注册中心），并分析了人口学，临床,治疗学,和结果数据来表征中国TTS患者的临床和结果特征。
结果：在2016年2月1日至2021年12月28日ChiTTS注册的112名入组患者中，平均年龄为59.4±18.7岁，27.7%是男性。共有41.1%的病人在住院期间出现呼吸及循环并发症,17.3%的患者发生心源性休克。物理触发器,呼吸困难,心动过速,年龄较小（<70岁）可预测住院并发症。随访期间的MACCE率为每名患者每年13.9%，全因死亡率为每名患者每年12.8%。住院并发症的TTS患者发生更长期的MACCE（24.6%vs.每患者年6.6%，P<0.001）和更高的全因死亡率（21.9%vs.每患者年6.6%，P=0.001）比没有的。Kaplan-Meier生存分析显示，在3年随访期间，有心动过速的TTS患者发生更多的MACCE（HR4.18；95％CI1.80-9.74；对数秩检验P<0.001）。在所有出院时的药物中，只有β受体阻滞剂与长期MACCE降低相关(HR:0.35;95%CI:0.12-0.996;P=0.049).
结论：我们在第一个中国TTS注册中调查了患者的临床和结局特征。心动过速TTS患者发生更多住院和长期不良心血管事件。
方法：我们建立了中国第一个Takotsubo综合征注册中心（ChiTTS注册中心），并分析了人口学，临床,治疗学,和结果数据来表征中国TTS患者的临床和结果特征。
结果：在2016年2月1日至2021年12月28日ChiTTS注册的112名入组患者中，平均年龄为59.4±18.7岁，27.7%是男性。共有41.1%的病人在住院期间出现呼吸及循环并发症,17.3%的患者发生心源性休克。物理触发器,呼吸困难,心动过速,年龄较小（<70岁）可预测住院并发症。随访期间的MACCE率为每名患者每年13.9%，全因死亡率为每名患者每年12.8%。住院并发症的TTS患者发生更长期的MACCE（24.6%vs.每患者年6.6%，P<0.001）和更高的全因死亡率（21.9%vs.每患者年6.6%，P=0.001）比没有的。Kaplan-Meier生存分析显示，在3年随访期间，有心动过速的TTS患者发生更多的MACCE（HR4.18；95％CI1.80-9.74；对数秩检验P<0.001）。在所有出院时的药物中，只有β受体阻滞剂与长期MACCE降低相关(HR:0.35;95%CI:0.12-0.996;P=0.049).
结论：我们在第一个中国TTS注册中调查了患者的临床和结局特征。心动过速TTS患者发生更多住院和长期不良心血管事件。
